PMC:7073332 / 430-1343 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"47","span":{"begin":358,"end":363},"obj":"Species"},{"id":"48","span":{"begin":460,"end":469},"obj":"Species"},{"id":"49","span":{"begin":470,"end":480},"obj":"Species"},{"id":"50","span":{"begin":534,"end":542},"obj":"Species"},{"id":"51","span":{"begin":608,"end":617},"obj":"Species"},{"id":"52","span":{"begin":618,"end":628},"obj":"Species"},{"id":"53","span":{"begin":746,"end":754},"obj":"Species"},{"id":"54","span":{"begin":839,"end":844},"obj":"Species"},{"id":"59","span":{"begin":312,"end":316},"obj":"Species"},{"id":"60","span":{"begin":429,"end":433},"obj":"Species"},{"id":"61","span":{"begin":809,"end":813},"obj":"Species"},{"id":"62","span":{"begin":890,"end":894},"obj":"Species"}],"attributes":[{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"Tax:9606"},{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"Tax:2697049"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"Tax:2697049"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"Tax:694009"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"Tax:2697049"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"Tax:2697049"},{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"Tax:694009"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"Tax:9606"},{"id":"A59","pred":"tao:has_database_id","subj":"59","obj":"Tax:694448"},{"id":"A60","pred":"tao:has_database_id","subj":"60","obj":"Tax:694448"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"Tax:694448"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"Tax:694448"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV–host interactome and drug targets in the human protein–protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Using network proximity analyses of drug targets and HCoV–host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":364,"end":371},"obj":"Body_part"},{"id":"T2","span":{"begin":372,"end":379},"obj":"Body_part"},{"id":"T3","span":{"begin":440,"end":447},"obj":"Body_part"},{"id":"T4","span":{"begin":500,"end":510},"obj":"Body_part"},{"id":"T5","span":{"begin":596,"end":604},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma84116"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma82740"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV–host interactome and drug targets in the human protein–protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Using network proximity analyses of drug targets and HCoV–host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T6","span":{"begin":470,"end":478},"obj":"Disease"},{"id":"T7","span":{"begin":534,"end":542},"obj":"Disease"},{"id":"T8","span":{"begin":618,"end":626},"obj":"Disease"},{"id":"T9","span":{"begin":746,"end":754},"obj":"Disease"}],"attributes":[{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV–host interactome and drug targets in the human protein–protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Using network proximity analyses of drug targets and HCoV–host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T2","span":{"begin":218,"end":219},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T3","span":{"begin":358,"end":371},"obj":"http://purl.obolibrary.org/obo/PR_000029067"},{"id":"T4","span":{"begin":839,"end":844},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"}],"text":"drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV–host interactome and drug targets in the human protein–protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Using network proximity analyses of drug targets and HCoV–host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T3","span":{"begin":0,"end":4},"obj":"Chemical"},{"id":"T4","span":{"begin":38,"end":43},"obj":"Chemical"},{"id":"T5","span":{"begin":108,"end":112},"obj":"Chemical"},{"id":"T6","span":{"begin":166,"end":180},"obj":"Chemical"},{"id":"T7","span":{"begin":166,"end":175},"obj":"Chemical"},{"id":"T8","span":{"begin":176,"end":180},"obj":"Chemical"},{"id":"T9","span":{"begin":255,"end":263},"obj":"Chemical"},{"id":"T10","span":{"begin":338,"end":342},"obj":"Chemical"},{"id":"T11","span":{"begin":364,"end":371},"obj":"Chemical"},{"id":"T12","span":{"begin":372,"end":379},"obj":"Chemical"},{"id":"T13","span":{"begin":500,"end":510},"obj":"Chemical"},{"id":"T14","span":{"begin":596,"end":604},"obj":"Chemical"},{"id":"T15","span":{"begin":792,"end":796},"obj":"Chemical"},{"id":"T16","span":{"begin":908,"end":913},"obj":"Chemical"}],"attributes":[{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_36044"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_36976"},{"id":"A14","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV–host interactome and drug targets in the human protein–protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Using network proximity analyses of drug targets and HCoV–host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs"}

{"project":"LitCovid-sentences","denotations":[{"id":"T6","span":{"begin":124,"end":400},"obj":"Sentence"},{"id":"T7","span":{"begin":401,"end":551},"obj":"Sentence"},{"id":"T8","span":{"begin":552,"end":755},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV–host interactome and drug targets in the human protein–protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Using network proximity analyses of drug targets and HCoV–host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs"}